March/April 2013 Vol 6, No 2

More than 1 in 3 American adults have at least one type of cardiovascular disease, which is the leading cause of death in the United States for men and women.1 The total annual burden of heart disease is estimated to be $312.6 billion in combined direct and indirect costs.1 In addition to an overall annual cost of more than $34 billion,2 heart failure is one of the main medical conditions necessitating acute hemodynamic support.

Careful Selection of Candidates for Percutaneous Ventricular Assist Device Is Crucial

According to a new Health Information and Management Systems Society (HIMSS) Leadership Survey ( 022813.pdf), which was released at the 2013 HIMSS annual conference, the government’s efforts to impact provider investments in information technology (IT) to qualify for Meaningful Use and International Classification of Diseases, Tenth Revision (ICD-10) conversions are paying off.

A ll available patient and medical information drives clinical decisions. However, the inability to provide evidence-based medical information when and where it is most useful can compromise efforts to deliver the best care. Payers and providers alike understand the importance of actionable content—namely, information designed to prompt or to suggest an action—but they struggle with how to deploy such information directly into the context of day-to-day patient care.

Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes pain, stiffness, swelling, and loss of function in the joints; it occurs when the patient’s immune system attacks healthy tissue. RA is ranked among the highest of all chronic diseases for its adverse impact on health-related quality of life (QOL), limitations in physical function, increased pain and fatigue, and diminished work performance and attendance.1

Assessing the Value of TNF-Alpha Blockers for Patients with Rheumatoid Arthritis

Fragile X syndrome (FXS) is the most common form of inherited intellectual disability, with cognitive and behavioral impairments of varying degrees that are associated with distinct physical features.1 This neurodevelopmental disorder is caused by the silencing of a single X-linked gene, the fragile X mental retardation 1 gene, and hence manifests primarily in males.

Rarity, Disease Heterogeneity, and a Pathway for Estimating Economic Burden

Regular readers of American Health & Drug Benefits know that I like to peruse the literature from consulting companies and industry-related think tanks. A recent report from PricewaterhouseCoopers (PwC)—Operating Performance in the Medtech Industry: Trends and Imperatives1—really caught my eye.

Results 1 - 6 of 6
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME